Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with S
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q2 2024 | SOYBEAN LECITHIN | ORAL | CAPSULE | 20.00 mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | POWDER, FOR SUSPENSION | 39mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET | 8mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET, EXTENDED RELEASE | 20mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | ORAL | TABLET, FILM COATED | 0.33 mg | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | RESPIRATORY (INHALATION) | AEROSOL, METERED | 0.10 %w/w | Correction | ||
| Q2 2024 | SOYBEAN LECITHIN | VAGINAL | CREAM | 1.00 %w/w | Correction | ||
| Q2 2024 | SHELLAC | ORAL | CAPSULE, LIQUID FILLED | NA | Deletion | ||
| Q2 2024 | SODIUM BISULFITE | OPHTHALMIC | SUSPENSION | 0.06 %w/w | Deletion | ||
| Q2 2024 | SODIUM HYDROXIDE | INTRAVENOUS | POWDER, FOR SOLUTION | ADJ PH | Deletion | ||
| Q1 2024 | SACCHARIN | ORAL | GRANULE, FOR SOLUTION | 16.00 mg | MDE Replacement | ||
| Q2 2024 | SACCHARIN | ORAL | GRANULE, FOR SOLUTION | 16mg | MDE Replacement | ||
| Q1 2024 | SIMETHICONE | ORAL | GRANULE, FOR SUSPENSION | 4.00 mg/ 5.00 ml | MDE Replacement | ||
| Q2 2024 | SIMETHICONE | ORAL | GRANULE, FOR SUSPENSION | 40mg | MDE Replacement | ||
| Q1 2024 | SIMETHICONE EMULSION | ORAL | TABLET, EXTENDED RELEASE | 0.08 mg | MDE Replacement | ||
| Q2 2024 | SIMETHICONE EMULSION | ORAL | TABLET, EXTENDED RELEASE | 2mg | MDE Replacement | ||
| Q1 2024 | SODIUM CHLORIDE | OPHTHALMIC | SUSPENSION/ DROPS | 0.51 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM CHLORIDE | OPHTHALMIC | SUSPENSION/ DROPS | 3mg | MDE Replacement | ||
| Q1 2024 | SODIUM CHLORIDE | RETROBULBAR | INJECTION | 0.86 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM CHLORIDE | RETROBULBAR | INJECTION | 648mg | MDE Replacement | ||
| Q1 2024 | SODIUM HYDROXIDE | INTRAMUSCULAR | INJECTION, SOLUTION | 0.13 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM HYDROXIDE | INTRAMUSCULAR | INJECTION, SOLUTION | 78mg | MDE Replacement | ||
| Q1 2024 | SODIUM HYDROXIDE | INTRAVENOUS | INJECTION, SOLUTION | 2.83 %w/v | MDE Replacement | ||
| Q2 2024 | SODIUM HYDROXIDE | INTRAVENOUS | INJECTION, SOLUTION | 78mg | MDE Replacement | ||
| Q1 2024 | SODIUM HYDROXIDE | OPHTHALMIC | GEL | 1.85 %w/w | MDE Replacement | ||
| Q2 2024 | SODIUM HYDROXIDE | OPHTHALMIC | GEL | 6mg | MDE Replacement | ||
| Q1 2024 | SORBITAN MONOOLEATE | ORAL | CAPSULE | 153.90 mg | MDE Replacement | ||
| Q2 2024 | SORBITAN MONOOLEATE | ORAL | CAPSULE | 200mg | MDE Replacement | ||
| Q1 2024 | SORBITOL SOLUTION | TOPICAL | LOTION | 10.70 %w/w | MDE Replacement | ||
| Q2 2024 | SORBITOL SOLUTION | TOPICAL | LOTION | 764mg | MDE Replacement | ||
| Q1 2024 | STEAROYL POLYOXYLGLYCERIDES | ORAL | CAPSULE | 260.00 mg | MDE Replacement | ||
| Q2 2024 | STEAROYL POLYOXYLGLYCERIDES | ORAL | CAPSULE | 2350mg | MDE Replacement | ||
| Q1 2024 | SUCROSE DISTEARATE | TOPICAL | CREAM | 5.00 %w/w | MDE Replacement | ||
| Q2 2024 | SUCROSE DISTEARATE | TOPICAL | CREAM | 25mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024